Jun 14, 2021
SAN FRANCISCO, June 14, 2021 —  Better Therapeutics, Inc.  (“Better Therapeutics”), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced its team is scheduled to participate in two virtual panel
Apr 20, 2021
SAN FRANCISCO, April 20, 2021 — Better Therapeutics, Inc., a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Dr. Risa Lavizzo-Mourey to its board of directors; she will also
Oct 07, 2020
Justin Zamirowski to lead upcoming launches of Better Therapeutics’ maturing prescription digital therapeutics product portfolio with a near term focus on type 2 diabetes and associated comorbidities. We recently  announced  the appointment of Justin Zamirowski as Chief Commercial Officer.
Oct 09, 2019
Today, we announced the publication of our  fifth peer-reviewed study  titled "Estimating the impact of novel digital therapeutics in type 2 diabetes and hypertension: Health economic analysis." Key findings were presented earlier this year at The International Society for Pharmacoeconomics and
Jul 24, 2019
Machine learning transformed data from using a digital therapeutic into digital biomarkers that predicted treatment response in individual participants. Today, we  announced  the  publication  of our latest study titled "Emergence of digital biomarkers to predict and modify treatment efficacy: a
Displaying 51 - 60 of 65